MDMB-CHMINACA

MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor,[1] and has been sold online as a designer drug.[2][3][4][5][6] It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB1, and an EC50 of 0.330 nM.[7] It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.[8]

MDMB-CHMINACA
Legal status
Legal status
  • CA: Schedule II
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
  • Illegal in Singapore and Switzerland
Identifiers
IUPAC name
  • Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazol-3-yl]formamido}-3,3-dimethylbutanoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H31N3O3
Molar mass385.508 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3
InChI
  • InChI=1S/C22H31N3O3/c1-22(2,3)19(21(27)28-4)23-20(26)18-16-12-8-9-13-17(16)25(24-18)14-15-10-6-5-7-11-15/h8-9,12-13,15,19H,5-7,10-11,14H2,1-4H3,(H,23,26)/t19-/m1/s1
  • Key:DGQMLBSSRFFINY-LJQANCHMSA-N

MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015.[9]

MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015.[10]

Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019.[11]

See also

References
  1. Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
  2. "MDMB-CHMINACA". Cayman Chemical. Retrieved 14 July 2015.
  3. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (August 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301–15. doi:10.1007/s00216-015-8612-7. PMID 25893797. S2CID 31838655.
  4. Prof. SA Savchuk (2014). "Detection methods of psychoactive substances and liquid chromotograoghy detection of metabolites" (PDF) (in Russian). Russian Ministry of Health. Retrieved 14 July 2015.
  5. "Идентификация синтетических каннабимиметиков MDMB-CHMINACA, MDMB-FUBINACA и их метаболитов" (in Russian). CTS "SCIENCE". Retrieved 14 July 2015.
  6. Hess C, Murach J, Krueger L, Scharrenbroch L, Unger M, Madea B, Sydow K (May 2017). "Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples". Drug Testing and Analysis. 9 (5): 721–733. doi:10.1002/dta.2030. PMID 27400642.
  7. Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106980
  8. "Очередная жертва спайса" (in Russian). Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from the original on 14 July 2015. Retrieved 13 July 2015.
  9. "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 14 July 2015.
  10. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.
  11. "Tretton ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 25 September 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.